A Phase I, Open-label, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Ceftolozane/Tazobactam in Healthy Japanese, Chinese and Caucasian Subjects.

Trial Profile

A Phase I, Open-label, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Ceftolozane/Tazobactam in Healthy Japanese, Chinese and Caucasian Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Ceftolozane/tazobactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial infections; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 26 Oct 2015 New trial record
    • 21 Sep 2015 Results presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top